Zevia 10-Q Discloses New Material Weakness in Journal-Entry Controls
ZVIA is trading near its 52-week low of $1.11 (12% above the low).
Summary
Zevia's Q3 10-Q repeats the already-reported 18.4% sales growth but newly discloses a material weakness in journal-entry controls, a $1.9 million litigation reserve and a $59.2 million contingent TRA liability.
Key Events · Earnings and Guidance · ZVIA
-
New Material Weakness Disclosed
Zevia identified a material weakness in internal control over financial reporting related to segregation of duties over manual journal entries in the quarter ended September 30, 2026. Management corrected the system-based journal-entry approval workflow but will monitor operating effectiveness through Q4 before concluding on remediation.
-
Q3 Sales Up 18.4%, Margin Improves
Net sales rose to $48.3 million from $40.8 million on 14.4% volume growth plus $1.2 million of pricing. Gross margin expanded to 46.4% from 45.6% and operating loss narrowed to $2.2 million from $2.9 million.
-
$1.9M Litigation Reserve Booked
The company recorded a $1.9 million reserve for the product-label claims case; a tentative settlement was reached April 20, 2026 and the plaintiff filed its motion for preliminary approval on September 14, 2026.
-
$59.2M TRA Liability Contingent
No TRA liability is recorded because the related deferred tax assets are not deemed more likely than not realizable; the liability would total $59.2 million if those benefits were determined to be fully realizable.
Analysis · ZVIA · Manufacturing
The headline numbers (Q3 net sales up 18.4% to $48.3 million, raised FY2026 outlook) were already public via the same-day 8-K, so the 10-Q's real news is what only the full report reveals: a newly identified material weakness in internal control over financial reporting tied to segregation of duties over manual journal entries. Management says it corrected the system-based journal-entry approval workflow and found no improper entries, but it will not conclude remediation until after the fourth quarter — meaning the weakness stays open into the next reporting cycle. The quarter itself was solid: gross margin rose to 46.4% from 45.6%, operating loss narrowed to $2.2 million from $2.9 million, and nine-month operating cash flow swung positive to $5.5 million from a $4.2 million use. Against that, the report quantifies a $1.9 million litigation reserve for the label-claims case (tentative settlement reached April 20, 2026, preliminary approval motion filed September 14, 2026) and a $59.2 million TRA liability that would come onto the balance sheet if the related deferred tax assets ever become more likely than not to be realized. The October 22, 2026 GP Investments preferred financing is detailed here for the first time in a periodic report: $15.0 million already funded, $5.0 million deferred until after the 2026 10-K and contingent on FY2026 net sales of at least $172.5 million and Adjusted EBITDA no worse than negative $3.0 million, with 6.00% cumulative dividends accruing from the earlier of the deferred closing, the 10-K filing or April 15, 2027.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ZVIA was trading at $1.24 on NYSE in the Manufacturing sector, with a market capitalization of approximately $92.8M. The 52-week trading range was $1.11 to $2.78. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.